Periodic fever syndromes, autoinflammatory diseases, Still’s disease and MAS/HLH
Philip Seo, MD, MHS
Johns Hopkins University
Baltimore, MD, United States
Disclosure(s): Amgen: Advisor or Review Panel Member (Ongoing); Janssen: Advisor or Review Panel Member (Terminated, October 3, 2022)
Robert Spiera, MD
Hosptial for Special Surgery
New York, NY, United States
Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); chemocentryx: Grant/Research Support (Ongoing); corbus: Grant/Research Support (Ongoing); Formation Biologics: Grant/Research Support (Ongoing); GSK: Consultant (Ongoing), Grant/Research Support (Ongoing); Inflarx: Grant/Research Support (Ongoing); Kadmon: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Principia: Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing)
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are two of the most common inflammatory rheumatic diseases affecting older adults. For decades, glucocorticoids have been the cornerstone of treatments for individuals with these diseases, with some data supporting the use of steroid-sparing agents such as methotrexate. IL-6 inhibitors have been approved and recommended for the treatment of GCA, and more recently approved for treatment of refractory PMR. However, there are several unanswered questions regarding the use of biologic agents in GCA and PMR including ideal timing of initiation, identification of individuals who would benefit from these, and duration of treatment including achieving drug-free remission.
This year's Great Debate showcases two experts in the field who will review the data around use of biologic therapies in PMR and GCA and argue for or against the use of advanced therapies at disease onset.
Panelist: Philip Seo, MD, MHS – Johns Hopkins University
Panelist: Robert Spiera, MD – Hosptial for Special Surgery
